Moreover, CD133 antigen expression has been identified in various types of solid tumours [5,9,10,16-18], and documented to be associated with patients' response to treatment and clinical outcome; in particular, CD133+ glioma cells were shown to exhibit resistance to radiation [17], and chemotherapy [18]. Here, PROM1 is linked to glioma.